All In Biotech

BLA 761108 · Alexion Pharm

Ultomiris

Ravulizumab-Cwvz · Injection · Complement Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Dec 21, 2018

Approved uses

8

Original approval plus efficacy supplements

Registered trials

47

30 Phase 3, 15 recruiting

FAERS reports

14,195

8,138 serious, 1,058 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS ULTOMIRIS, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [see Warnings and Precautions (5.1) ] . Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early . Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ULTOMIRIS, unless the risks of delaying therapy with ULTOMIRIS outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional...

What it is approved for

From the label in effect Oct 29, 2026.

ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. ( 1.3 ) the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ( 1.4 ) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression ( 1.5 ). This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether ULTOMIRIS slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. 1.1 Paroxysmal Nocturnal Hemoglobinuria ULTOMIRIS is indicated for the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). 1.2 Atypical Hemolytic Uremic Syndrome ULTOMIRIS is indicated for the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E....

Mechanism: Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the membrane attack complex [MAC or C5b-9]) thus preventing MAC formation. ULTOMIRIS inhibits terminal complement-mediated intravascular hemolysis in patients with PNH and complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS. The precise mechanism by which ravulizumab-cwvz exerts its therapeutic effect in gMG patients is unknown, but is...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ULTOMIRIS · RAVULIZUMAB-CWVZ 300MG/30ML(10MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ravulizumab" as an intervention, any sponsor and status, largest first.

All 47 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,819
  • asthenia925
  • drug ineffective775
  • headache772
  • death677
  • off label use581
  • dyspnoea548
  • muscular weakness532
  • myasthenia gravis511
  • malaise483
  • pain452
  • haemoglobin decreased423

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20182
2019599
2020434
2021433
2022512
20232,079
20244,319
20253,090
20262,726

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ultomiris (Ravulizumab-Cwvz)

2024 spending

$233M

Beneficiaries

701

3,951 claims

Per beneficiary

$332,291

$2,110.49 per unit

View as table
YearSpending
2020$10,577,129
2021$15,592,736
2022$46,988,003
2023$159,533,070
2024$232,936,291

Part B: Ultomiris (Ravulizumab-Cwvz) · HCPCS J1303

2024 spending

$609M

Beneficiaries

1,844

10,789 claims

Per beneficiary

$330,448

2024 ASP limit $221.37 per unit

View as table
YearSpending
2020$146,656,849
2021$177,654,131
2022$263,257,392
2023$471,519,422
2024$609,346,340

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 53 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.